Vertex Statement On Confirmation Of Trikafta Funding

Vertex welcomes the announcement by Pharmac confirming
the listing of Trikafta® (elexacaftor/tezacaftor/ivacaftor
and ivacaftor) on the Pharmaceutical Schedule from 1 April
2023 for eligible New Zealanders with cystic fibrosis ages 6
years and older who have at least one F508del
mutation in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene.

“We are delighted
that the Pharmac Board has confirmed New Zealanders living
with cystic fibrosis, including children as young as six,
will have reimbursed access to Trikafta from 1 April,”
said Sabrina Barbic, Senior Country Manager, Vertex
Australia and New Zealand. “In addition, Pharmac has
recognised that every eligible patient should have access
and acknowledges the value Trikafta can bring, not only to
people living with cystic fibrosis and their caregivers, but
also the wider society.”

At Vertex
our ambition is to discover and develop transformative
medicines for cystic fibrosis that reach all people with the
disease, regardless of genotype or age. We continue to
invest in clinical trials with our existing treatments, as
well as research and development into new approaches, such
as mRNA and gene editing
technologies.

© Scoop Media